Developer docs
API playgroundTry for free, no card

Search company profiles

Ensoma

Full company profile

uuid0000367

Namestring
Ensoma
Legal namestring
Ensoma, Inc.
Websiteurl
ensoma.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Ensoma is a Boston-based, clinical-stage genomic medicine company founded in 2019/2020 that develops in vivo hematopoietic stem cell (HSC) engineering therapies. Its proprietary Engenious Platform combines off-the-shelf, high-capacity virus-like particles (VLPs) — capable of carrying up to 35 kilobases of genetic cargo — with proprietary CRISPR-Cas and base editing tools to engineer HSCs directly within the patient. This in vivo architecture eliminates the ex vivo cell harvesting, manufacturing, and myeloablative conditioning required by conventional gene and cell therapies, with the goal of one-time, durable treatments potentially administered on an outpatient basis.

The lead clinical program, EN-374, is in a multicenter Phase 1/2 trial (NCT06876363) for X-linked chronic granulomatous disease (X-CGD), a rare immunodeficiency affecting 1 in 100,000–200,000 live births. EN-374 became the first in vivo HSC-directed gene insertion therapy to enter clinical evaluation when the first patient was dosed in December 2025, and has received FDA Orphan Drug and Rare Pediatric Disease designations as well as UK MHRA Clinical Trial Authorization. The pipeline additionally includes a sickle cell disease program using in vivo base editing to reactivate fetal hemoglobin, and a solid tumor program generating multiplexed CAR-M, NK, and T cells from engineered HSCs for HER2+ tumors.

Ensoma operates as a pre-revenue biotech funded by venture and strategic capital — approximately $138 million disclosed across a January 2023 $85 million financing and September 2025 $53 million round, with a syndicate including Gilead, 5AM Ventures, the Bill & Melinda Gates Foundation, Qatar Investment Authority, Viking Global Investors, and others. The company acquired Danish CRISPR-Cas specialist Twelve Bio ApS in February 2023 to deepen its gene editing toolkit. Future revenue is expected to derive from commercialization of one-time gene therapies via specialty pharmacies and designated treatment centers, with potential price points comparable to other approved gene therapies (e.g., $3.5M for hemophilia B).

Short descriptiontext

Ensoma is a Boston-based clinical-stage biotech developing in vivo HSC engineering therapies via its Engenious Platform, which combines high-capacity VLPs with CRISPR-Cas and base editing to deliver one-time gene therapies for X-CGD, sickle cell disease, and solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vivo gene therapy, hematopoietic stem cell engineering, CRISPR gene editing, virus-like particle delivery, genomic medicines
Industry3 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
In Vivo Gene Therapy
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene therapy development and commercialization
TypeOne Time License
Description

Ensoma is developing one-time, durable gene therapies for genetic diseases (X-CGD, sickle cell disease) and cancer (solid tumors). As a clinical-stage company, it operates pre-revenue, funded by private investors and strategic partnerships. Revenue would derive from commercialization of its pipeline therapies upon regulatory approval.

ensoma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Engenious
Description

The company's proprietary technology platform combining virus-like particles (VLPs) with advanced gene engineering tools for in vivo HSC engineering.

ensoma.com
Core offering1 text field

Ensoma develops one-time, in vivo hematopoietic stem cell (HSC) engineering gene therapies through its proprietary Engenious Platform, which combines high-capacity virus-like particles (VLPs) with proprietary CRISPR-Cas and base editing tools. Its lead clinical-stage product EN-374 delivers a CYBB transgene to HSCs in vivo for X-linked chronic granulomatous disease (X-CGD), and the pipeline extends to in vivo base editing for sickle cell disease and multiplexed in vivo CAR-M, NK, and T cell therapy for solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • EN-374 Phase 1/2 trial demonstrated tolerability in first participant with all adverse events being low-grade; no serious AEs or dose-limiting toxicities observed
+3 more records
Product overview1 text field

Ensoma is an in vivo hematopoietic stem cell (HSC) engineering company developing one-time, off-the-shelf therapies through its Engenious Platform. The platform combines high-capacity virus-like particles (VLPs) with proprietary CRISPR-Cas and base editing tools to engineer HSCs directly within the body. Lead clinical program EN-374 (for X-linked chronic granulomatous disease) is in Phase 1/2 trials. The pipeline includes programs for sickle cell disease (base editing to reactivate fetal hemoglobin) and solid tumors (multiplexed CAR-M, NK, T cell therapy).

Product and service3 records
1EN-374
CategoryGene therapy product
Description

First-in-class in vivo hematopoietic stem cell (HSC)-directed gene insertion therapy for X-linked chronic granulomatous disease (X-CGD). Uses virus-like particles (VLPs) to deliver the CYBB transgene to HSCs to restore NADPH oxidase function in neutrophils; currently in a multicenter Phase 1/2 trial (NCT06876363) in the U.S. and U.K. for adult and pediatric X-CGD patients.

2Sickle Cell Disease Program
CategoryGene therapy product (pipeline)
Description

Preclinical in vivo HSC engineering program using base editing to reactivate fetal hemoglobin (HbF) for treatment of sickle cell disease, designed to simplify the patient treatment journey compared with complex ex vivo approaches that require blood transfusions, stem cell mobilization, myeloablative conditioning, and extended hospital stays.

3Solid Tumor CAR Program
CategoryCell therapy product (pipeline)
Description

Preclinical in vivo HSC engineering program generating multiplexed CAR-M, NK, and T cells for solid tumor treatment through lineage-restricted expression of CARs, with preclinical proof-of-concept demonstrated in HER2+ tumor models showing durable tumor control and prolonged survival compared to controls.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-09
Description

Profluent Bio and Ensoma entered a strategic collaboration to develop AI-designed base editors for in vivo hematopoietic stem cell therapies. The companies aim to leverage Profluent's AI technology to create advanced gene editing tools that could improve treatments for hematologic and immune diseases. Located in Emeryville, California.

2Twelve Bio ApS
Strategic tierMajorTypeOthersAnnounced on2023-02-09
Description

Ensoma completed the acquisition of Twelve Bio ApS, a Danish gene editing company specializing in next-generation CRISPR-Cas medicines, following Danish regulatory approval. Key personnel from Twelve Bio joined Ensoma's leadership and advisory teams as part of the integration. The acquisition enhanced Ensoma's CRISPR technology capabilities as part of the $85M financing.

ensoma.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Locanabio
TypeDirect peer
Description

RNA-targeting genetic medicines company developing treatments for neuromuscular and neurodegenerative diseases. Comparable as Ensoma's CEO Jim Burns previously led Locanabio, and both companies operate in the in vivo genetic medicines space with platform-based approaches.

TypeEmerging player
Description

Preclinical-stage RNA editing and gene therapy company with platform technologies for in vivo gene correction. Comparable as an emerging player in the in vivo gene editing space; Ensoma's VP Clinical Drew Dietz previously led clinical development at Shape.

TypeEmerging player
Description

Preclinical-stage epigenetic editing company developing gene silencing and activation therapies. Comparable as an emerging platform-based gene regulation company with related leadership pedigree (Ensoma's SVP Legal previously SVP at Chroma).

4bluebird bio
TypeDirect peer
Description

Pioneer in ex vivo lentiviral gene therapy with approved products in sickle cell disease (Lyfgenia) and beta-thalassemia. Directly comparable as a competing gene therapy approach for the same hemoglobinopathy indication Ensoma targets with in vivo base editing, and Drew Dietz (VP Clinical) led late-stage trials at bluebird.

TypeDirect peer
Description

Co-developer of Casgevy (exa-cel), the first FDA-approved CRISPR/Cas9 gene therapy, partnered with Vertex for sickle cell disease and beta-thalassemia. Most direct competitor to Ensoma's in vivo SCD program using ex vivo CRISPR editing of patient HSCs.

TypeDirect peer
Description

Clinical-stage base editing company developing in vivo and ex vivo base editing therapies across hemoglobinopathies, oncology, and rare diseases. Directly comparable as Ensoma's base editing-based sickle cell program uses similar underlying editing chemistry against Beam's pipeline.

TypeDirect peer
Description

Leader in in vivo CRISPR/Cas9 and Cas9-based gene editing with clinical-stage programs in transthyretin amyloidosis and hereditary angioedema. Comparable as a clinical-stage in vivo gene editing company pursuing systemic delivery of editing payloads, though Intellia uses LNP delivery rather than Ensoma's VLP approach.

TypeDirect peer
Description

Clinical-stage in vivo base editing company targeting cardiovascular diseases with a one-time treatment approach. Highly comparable as a fellow in vivo gene editing platform company that has validated the systemic in vivo editing approach clinically, addressing a similar regulatory and capital markets landscape.

TypeDirect peer
Description

Clinical-stage CRISPR gene editing company developing ex vivo and in vivo gene editing therapies for hemoglobinopathies and ophthalmologic indications. Comparable as a clinical-stage editing company with overlapping hemoglobinopathy focus and similar platform-based approach.

TypeEmerging player
Description

Clinical-stage gene editing company developing prime editing technology for precise genetic corrections across multiple diseases. Comparable as an emerging gene editing platform pursuing broad indication coverage, though using a distinct editing chemistry (prime editing) versus Ensoma's base editing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ensoma

In Vivo Gene Therapyensoma.com

Ensoma is a Boston-based clinical-stage biotech developing in vivo HSC engineering therapies via its Engenious Platform, which combines high-capacity VLPs with CRISPR-Cas and base editing to deliver one-time gene therapies for X-CGD, sickle cell disease, and solid tumors.

What Ensoma does

Ensoma is a Boston-based, clinical-stage genomic medicine company founded in 2019/2020 that develops in vivo hematopoietic stem cell (HSC) engineering therapies. Its proprietary Engenious Platform combines off-the-shelf, high-capacity virus-like particles (VLPs) — capable of carrying up to 35 kilobases of genetic cargo — with proprietary CRISPR-Cas and base editing tools to engineer HSCs directly within the patient. This in vivo architecture eliminates the ex vivo cell harvesting, manufacturing, and myeloablative conditioning required by conventional gene and cell therapies, with the goal of one-time, durable treatments potentially administered on an outpatient basis.

The lead clinical program, EN-374, is in a multicenter Phase 1/2 trial (NCT06876363) for X-linked chronic granulomatous disease (X-CGD), a rare immunodeficiency affecting 1 in 100,000–200,000 live births. EN-374 became the first in vivo HSC-directed gene insertion therapy to enter clinical evaluation when the first patient was dosed in December 2025, and has received FDA Orphan Drug and Rare Pediatric Disease designations as well as UK MHRA Clinical Trial Authorization. The pipeline additionally includes a sickle cell disease program using in vivo base editing to reactivate fetal hemoglobin, and a solid tumor program generating multiplexed CAR-M, NK, and T cells from engineered HSCs for HER2+ tumors.

Ensoma operates as a pre-revenue biotech funded by venture and strategic capital — approximately $138 million disclosed across a January 2023 $85 million financing and September 2025 $53 million round, with a syndicate including Gilead, 5AM Ventures, the Bill & Melinda Gates Foundation, Qatar Investment Authority, Viking Global Investors, and others. The company acquired Danish CRISPR-Cas specialist Twelve Bio ApS in February 2023 to deepen its gene editing toolkit. Future revenue is expected to derive from commercialization of one-time gene therapies via specialty pharmacies and designated treatment centers, with potential price points comparable to other approved gene therapies (e.g., $3.5M for hemophilia B).

Ensoma firmographics

Firmographics
Name
Ensoma
Legal name
Ensoma, Inc.
Website
https://ensoma.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Ensoma is a Boston-based clinical-stage biotech developing in vivo HSC engineering therapies via its Engenious Platform, which combines high-capacity VLPs with CRISPR-Cas and base editing to deliver one-time gene therapies for X-CGD, sickle cell disease, and solid tumors.
Ownership category
akta.pro rank

Ensoma industry classification

Industry
Product category
In Vivo Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • In vivo gene therapy
  • Hematopoietic stem cell engineering
  • CRISPR gene editing
  • Virus-like particle delivery
  • Genomic medicines

Where Ensoma is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ensoma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Gene therapy development and commercialization: Ensoma is developing one-time, durable gene therapies for genetic diseases (X-CGD, sickle cell disease) and cancer (solid tumors). As a clinical-stage company, it operates pre-revenue, funded by private investors and strategic partnerships. Revenue would derive from commercialization of its pipeline therapies upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Ensoma product offering

Product offering

Core offering

Ensoma develops one-time, in vivo hematopoietic stem cell (HSC) engineering gene therapies through its proprietary Engenious Platform, which combines high-capacity virus-like particles (VLPs) with proprietary CRISPR-Cas and base editing tools. Its lead clinical-stage product EN-374 delivers a CYBB transgene to HSCs in vivo for X-linked chronic granulomatous disease (X-CGD), and the pipeline extends to in vivo base editing for sickle cell disease and multiplexed in vivo CAR-M, NK, and T cell therapy for solid tumors.

Product overview

Ensoma is an in vivo hematopoietic stem cell (HSC) engineering company developing one-time, off-the-shelf therapies through its Engenious Platform. The platform combines high-capacity virus-like particles (VLPs) with proprietary CRISPR-Cas and base editing tools to engineer HSCs directly within the body. Lead clinical program EN-374 (for X-linked chronic granulomatous disease) is in Phase 1/2 trials. The pipeline includes programs for sickle cell disease (base editing to reactivate fetal hemoglobin) and solid tumors (multiplexed CAR-M, NK, T cell therapy).

Differentiator

Problem solved

Functional benefit

Brands

  • Engenious: The company's proprietary technology platform combining virus-like particles (VLPs) with advanced gene engineering tools for in vivo HSC engineering.

Products and services

  • EN-374 First-in-class in vivo hematopoietic stem cell (HSC)-directed gene insertion therapy for X-linked chronic granulomatous disease (X-CGD). Uses virus-like particles (VLPs) to deliver the CYBB transgene to HSCs to restore NADPH oxidase function in neutrophils; currently in a multicenter Phase 1/2 trial (NCT06876363) in the U.S. and U.K. for adult and pediatric X-CGD patients.
  • Sickle Cell Disease Program Preclinical in vivo HSC engineering program using base editing to reactivate fetal hemoglobin (HbF) for treatment of sickle cell disease, designed to simplify the patient treatment journey compared with complex ex vivo approaches that require blood transfusions, stem cell mobilization, myeloablative conditioning, and extended hospital stays.
  • Solid Tumor CAR Program Preclinical in vivo HSC engineering program generating multiplexed CAR-M, NK, and T cells for solid tumor treatment through lineage-restricted expression of CARs, with preclinical proof-of-concept demonstrated in HER2+ tumor models showing durable tumor control and prolonged survival compared to controls.

Quantifiable outcome

  • EN-374 Phase 1/2 trial demonstrated tolerability in first participant with all adverse events being low-grade; no serious AEs or dose-limiting toxicities observed
  • +3 more outcomes

Companies that use Ensoma

Customer profile

Segments3 records

Ideal customer profiles3 records

Ensoma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Ensoma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and major.

  • Profluent BiocoreStrategic or Co-development Partner · 9 December 2025Profluent Bio and Ensoma entered a strategic collaboration to develop AI-designed base editors for in vivo hematopoietic stem cell therapies. The companies aim to leverage Profluent's AI technology to create advanced gene editing tools that could improve treatments for hematologic and immune diseases. Located in Emeryville, California.
  • Twelve Bio ApSmajorOthers · 9 February 2023Ensoma completed the acquisition of Twelve Bio ApS, a Danish gene editing company specializing in next-generation CRISPR-Cas medicines, following Danish regulatory approval. Key personnel from Twelve Bio joined Ensoma's leadership and advisory teams as part of the integration. The acquisition enhanced Ensoma's CRISPR technology capabilities as part of the $85M financing.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Ensoma competitors and assessment

Company assessment

Direct peers

  • Locanabio: RNA-targeting genetic medicines company developing treatments for neuromuscular and neurodegenerative diseases. Comparable as Ensoma's CEO Jim Burns previously led Locanabio, and both companies operate in the in vivo genetic medicines space with platform-based approaches.
  • bluebird bio: Pioneer in ex vivo lentiviral gene therapy with approved products in sickle cell disease (Lyfgenia) and beta-thalassemia. Directly comparable as a competing gene therapy approach for the same hemoglobinopathy indication Ensoma targets with in vivo base editing, and Drew Dietz (VP Clinical) led late-stage trials at bluebird.
  • CRISPR Therapeutics: Co-developer of Casgevy (exa-cel), the first FDA-approved CRISPR/Cas9 gene therapy, partnered with Vertex for sickle cell disease and beta-thalassemia. Most direct competitor to Ensoma's in vivo SCD program using ex vivo CRISPR editing of patient HSCs.
  • Beam Therapeutics: Clinical-stage base editing company developing in vivo and ex vivo base editing therapies across hemoglobinopathies, oncology, and rare diseases. Directly comparable as Ensoma's base editing-based sickle cell program uses similar underlying editing chemistry against Beam's pipeline.
  • Intellia Therapeutics: Leader in in vivo CRISPR/Cas9 and Cas9-based gene editing with clinical-stage programs in transthyretin amyloidosis and hereditary angioedema. Comparable as a clinical-stage in vivo gene editing company pursuing systemic delivery of editing payloads, though Intellia uses LNP delivery rather than Ensoma's VLP approach.
  • Verve Therapeutics: Clinical-stage in vivo base editing company targeting cardiovascular diseases with a one-time treatment approach. Highly comparable as a fellow in vivo gene editing platform company that has validated the systemic in vivo editing approach clinically, addressing a similar regulatory and capital markets landscape.
  • Editas Medicine: Clinical-stage CRISPR gene editing company developing ex vivo and in vivo gene editing therapies for hemoglobinopathies and ophthalmologic indications. Comparable as a clinical-stage editing company with overlapping hemoglobinopathy focus and similar platform-based approach.

Emerging players

  • Shape Therapeutics: Preclinical-stage RNA editing and gene therapy company with platform technologies for in vivo gene correction. Comparable as an emerging player in the in vivo gene editing space; Ensoma's VP Clinical Drew Dietz previously led clinical development at Shape.
  • Chroma Medicine: Preclinical-stage epigenetic editing company developing gene silencing and activation therapies. Comparable as an emerging platform-based gene regulation company with related leadership pedigree (Ensoma's SVP Legal previously SVP at Chroma).
  • Prime Medicine: Clinical-stage gene editing company developing prime editing technology for precise genetic corrections across multiple diseases. Comparable as an emerging gene editing platform pursuing broad indication coverage, though using a distinct editing chemistry (prime editing) versus Ensoma's base editing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Ensoma social profiles

Digital presence

Ensoma compliance and trust

Trust signal

Compliance2 records

Ensoma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ensoma leadership team

Management profile

Number of profiles

Profiles11 records

Ensoma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ensoma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ensoma

What does Ensoma do?

Ensoma develops one-time, in vivo hematopoietic stem cell (HSC) engineering gene therapies through its proprietary Engenious Platform, which combines high-capacity virus-like particles (VLPs) with proprietary CRISPR-Cas and base editing tools. Its lead clinical-stage product EN-374 delivers a CYBB transgene to HSCs in vivo for X-linked chronic granulomatous disease (X-CGD), and the pipeline extends to in vivo base editing for sickle cell disease and multiplexed in vivo CAR-M, NK, and T cell therapy for solid tumors.

Is Ensoma a public or private company?

Ensoma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ensoma founded?

Ensoma was founded in 2020. It employs 11 to 50 people.

Where is Ensoma based?

Ensoma is headquartered in Boston, United States, in the North America region.

How does Ensoma make money?

One revenue line is on record: gene therapy development and commercialization.

Who are Ensoma's main competitors?

Direct peers on record are Locanabio, bluebird bio, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics, Verve Therapeutics and Editas Medicine. Emerging players are Shape Therapeutics, Chroma Medicine and Prime Medicine.

Does Ensoma have an API?

No public API is recorded for Ensoma.

What industry is Ensoma in?

Ensoma's product category is In Vivo Gene Therapy. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
QuotedDataRTW Biotech makes 16.5% half-year return as surge in listed drug developers outweighs write-down of EnsomaRTW Biotech reported a 16.5% half-year return, driven by a 21.8% gain in public holdings, despite a 1.6% NAV drop from a write-down of Ensoma. The write-down followed a lack of positive clinical data for Ensoma's lead therapy. The company's shares remain at an 18.5% discount to NAV.FierceBiotechEnsoma sheds more staff, pauses preclinical programs to home in on lead gene therapyBoston biotech Ensoma is conducting another round of layoffs and pausing preclinical programs to concentrate resources on its lead gene therapy, EN-374, for X-linked chronic granulomatous disease. The company previously reduced its workforce by half last November and now aims to advance clinical validation of its platform once additional funding is secured. Takeda was originally a collaborator in Ensoma's debut but is not currently active in the reported restructuring event.BioSpaceEnsoma to Present Clinical Safety Data from First Participant Dosed with In Vivo HSC Engineering Therapy at ASGCT Annual MeetingEnsoma will present initial clinical safety data from the first participant dosed with EN-374, an in vivo HSC gene therapy for X-linked chronic granulomatous disease, at the ASGCT Annual Meeting. The data show the treatment was well tolerated with only low-grade adverse events and no serious AEs. Follow-up for efficacy will be reported later.Labiotech.euSeven companies advancing sickle cell disease treatment in 2026Seven companies are advancing sickle cell disease treatments in 2026, including Beam Therapeutics, Ensoma, and Agios Pharmaceuticals. Beam's base-editing therapy aims to raise fetal hemoglobin above 60%, while Agios's mitapivat met phase 3 endpoints. In vivo and oral approaches seek to simplify access beyond Casgevy's ex vivo model.BioSpaceEnsoma Announces Clearance of U.K. Clinical Trial Authorization Application for EN-374, First In Vivo HSC-Directed Gene Insertion TherapyEnsoma announced that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared its clinical trial authorization application for EN-374, enabling the initiation of a Phase 1/2 trial at U.K. sites for the treatment of X-linked chronic granulomatous disease. The clearance comes shortly after the first U.S. patient was successfully dosed with EN-374 in the multinational study, marking a defining milestone for the first-in-class in vivo HSC-directed gene insertion therapy. EN-374 uses virus-like particles to deliver a CYBB transgene to hematopoietic stem cells, with the goal of restoring immune function in patients with this rare genetic disorder affecting approximately 1 in 100,000-200,000 live births worldwide.Business Wire BlogEnsoma Announces Clearance of U.K. Clinical Trial Authorization Application for EN-374, First In Vivo HSC-Directed Gene Insertion TherapyEnsoma announced the clearance of its clinical trial authorization application from the U.K. MHRA for its EN-374 therapy, allowing it to initiate Phase 1/2 clinical trials for X-linked chronic granulomatous disease. The company recently dosed the first patient in the U.S., and the trial aims to evaluate safety, tolerability, pharmacodynamics, and efficacy biomarkers.Business Wire BlogProfluent Bio Announces Strategic Collaboration with Ensoma to Develop AI-Designed Base Editors for In Vivo Hematopoietic Stem Cell TherapiesProfluent Bio announced a strategic collaboration with Ensoma to develop AI-designed base editors for in vivo hematopoietic stem cell therapies, combining Profluent's AI-designed deaminases with Ensoma's gene editing scaffolds and helper-dependent adenovirus delivery systems. The partnership aims to create potentially durable treatments for hematologic and immune diseases by enabling next-generation in vivo therapies that balance activity and precision. Both companies' CEOs expressed enthusiasm about the collaboration's potential to advance the next wave of gene editing therapeutics.FinSMEsEnsoma Raises $53M in FundingEnsoma, a Boston-based HSC engineering company, raised $53M from Gilead and other investors. The funds will support its Phase 1/2 trial for EN-374 in X-linked chronic granulomatous disease and expand its platform for immuno-oncology and sickle cell disease.Pulse 2.0Ensoma: $53 Million Secured To Advance Stem Cell Therapies And Global Clinical ImpactEnsoma, a biotechnology company developing one-time in vivo stem cell therapies, has closed a $53 million funding round backed by investors including Gilead, 5AM Ventures, and the Gates Foundation. The funding will support advancing its Phase 1/2 clinical trial for EN-374 targeting X-linked chronic granulomatous disease (X-CGD), as well as platform development for applications in immuno-oncology and sickle cell disease. The company stated the financing marks its transition to a clinical-stage company with participants now recruiting for the trial.